Related Experiment Videos
Lecithin: cholesterol acyltransferase in liver disease
C H Florén1, C H Chen, J Franzén
1Department of Medicine, University Hospital, Lund, Sweden.
Scandinavian Journal of Clinical and Laboratory Investigation
|October 1, 1987
Summary
In liver disease, lower lecithin: cholesterol acyltransferase (LCAT) activity is mainly due to reduced LCAT mass. This study measured LCAT mass, activity, and cholesterol esterification in liver disease patients.
Area of Science:
- Biochemistry
- Clinical Chemistry
- Hepatology
Background:
- Lecithin: cholesterol acyltransferase (LCAT) activity is crucial for cholesterol metabolism.
- LCAT activity is often altered in liver disease, but LCAT mass data is lacking.
Purpose of the Study:
- To investigate LCAT mass concentration in patients with liver disease.
- To correlate LCAT mass with LCAT activity, cholesterol esterification rate, and liver disease severity markers.
Main Methods:
- Measured plasma LCAT mass, LCAT activity, and cholesterol esterification rate.
- Analyzed data from 19 cholestatic and 21 non-cholestatic liver disease patients.
- Correlated LCAT parameters with serum albumin, pre-albumin, bilirubin, and bile salts.
Main Results:
- LCAT mass positively correlated with albumin and pre-albumin (p<0.001).
- LCAT mass negatively correlated with bilirubin and bile salts (p<0.01), indicating disease severity.
- Plasma LCAT mass strongly correlated with LCAT activity (r=0.88) and cholesterol esterification rate (r=0.73) (p<0.001).
Conclusions:
- Reduced LCAT activity and cholesterol esterification in liver disease are primarily caused by decreased LCAT mass.
- LCAT mass serves as a reliable indicator of liver function and disease severity.